Shots:

• The company initiates P-III OASIS program to evaluate the efficacy and safety of elinzanetant (120mg- qd) in 1300 patients with vasomotor symptoms during menopause at 200+ centers across 20+ countries
• The design and dosing of the P-III clinical development program is based on the results from two P-II studies i.e.- P-Ib/IIa RELENT-1 & P-IIb SWITCH-1 study for elinzanetant
• The therapy is currently under development as a non-hormonal- dual neurokinin-1-3 receptor antagonist. In Sept’20- Bayer has completed the acquisition of KaNDy to expand its drug development pipeline in women’s healthcare

| Ref: Businesswire | Image: Shanghai Daily